TENAX THERAPEUTICS, INC.: 10-Q filed 2019-05-15

Name: TENAX THERAPEUTICS, INC.: 10-Q filed 2019-05-15
Creator: TENAX THERAPEUTICS, INC.

What TENAX THERAPEUTICS, INC. reported in its quarterly report filed 2019-05-15 (fiscal Q1 2019): 31 published measures, 66 facts as tagged in accession 0001654954-19-006116.

This filing

Form: 10-Q (quarterly report)
Filed: 2019-05-15
Fiscal period: fiscal Q1 2019
Accession: 0001654954-19-006116 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TENAX THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2019-03-31	11,456,745	USD
At 2018-12-31	13,337,200	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2019-03-31	1,116,905	USD
At 2018-12-31	1,565,669	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2019-03-31	10,339,840	USD
At 2018-12-31	11,771,531	USD
At 2018-03-31	7,987,844	USD
At 2017-12-31	8,881,861	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2019-03-31	10,322,205	USD
At 2018-12-31	12,367,321	USD
At 2018-03-31	2,993,240	USD
At 2017-12-31	1,604,810	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	1,617,445	USD	90
2018-01-01 to 2018-03-31	1,192,967	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	-2,132,811	USD	90
2018-01-01 to 2018-03-31	-1,558,465	USD	90

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	3,574	USD	90
2018-01-01 to 2018-03-31	3,105	USD	90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	96,500	USD	90
2018-01-01 to 2018-03-31	0	USD	90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	-8,805	USD	90
2018-01-01 to 2018-03-31	2,946,895	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2019-03-31	-229,391,518	USD
At 2018-12-31	-227,801,743	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2019-03-31	10,462	USD
At 2018-12-31	8,525	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	0	USD	90
2018-01-01 to 2018-03-31	138,858	USD	90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	1,661,776	USD	90
2018-01-01 to 2018-03-31	1,223,054	USD	90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2019-03-31	11,190,961	USD
At 2018-12-31	13,320,240	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2019-03-31	1,014,175	USD
At 2018-12-31	1,565,669	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2019-03-31	596,809	USD
At 2018-12-31	749,814	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	-1,661,776	USD	90
2018-01-01 to 2018-03-31	-1,223,054	USD	90

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	-1,179,009	USD	90
2018-01-01 to 2018-03-31	-1,164,466	USD	90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	-482,767	USD	90
2018-01-01 to 2018-03-31	-58,588	USD	90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2019-03-31	6,154,434	shares
At 2018-12-31	3,792,249	shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2019-03-31	1,805	USD
At 2018-12-31	516	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2019-03-31	246,887	USD
At 2018-12-31	0	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2019-03-31	247,823	USD
At 2018-12-31	0	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2019-03-31	230,359	USD
At 2018-12-31	581,646	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2019-03-31	219,897	USD
At 2018-12-31	573,121	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2019-03-31	8,435	USD
At 2018-12-31	8,435	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2019-03-31	417,366	USD
At 2018-12-31	815,855	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	1,617,445	USD	90
2018-01-01 to 2018-03-31	1,192,967	USD	90

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	1,616,156	USD	90
2018-01-01 to 2018-03-31	1,203,824	USD	90

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	1,000	USD	90
2018-01-01 to 2018-03-31	3,000	USD	90

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	-44,331	USD	90
2018-01-01 to 2018-03-31	-30,087	USD	90

Inspect the source

Entity: TENAX THERAPEUTICS, INC. / CIK 0000034956
Captured: 2026-09-19T14:46:45.117Z
SEC response SHA-256: 3f4f90f5f823d316ffb20bc63506ae090888657f5ff1cb9568439e153f028cf5

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000034956.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))